Autoimmune Disease Treatment
Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 28, 2026
Key Takeaways
Autoimmune disease treatment focuses on reducing inflammation and calming an overactive immune system. Remission and symptom control are achievable with the right options.
Conventional medications fall into five categories (NSAIDs, corticosteroids, DMARDs, biologics, and replacement therapy). Each has distinct mechanisms and trade-offs that patients should discuss with their care team.
Root causes include genetic predisposition, environmental exposures, gut microbiome alterations, and hormonal influences. Common flare triggers range from infections and stress to sleep disruption and dietary factors.
Evidence-based lifestyle strategies such as the Mediterranean diet, high-fiber intake, omega-3 fatty acids, consistent sleep, and stress management can meaningfully reduce autoimmune disease activity alongside medical treatment.
Mirror Plastic Surgery Peptides offers physician-led, lab-driven peptide protocols that complement conventional care and support personalized autoimmune disease management.
Schedule Your Autoimmune Peptide Consultation
Conventional Autoimmune Disease Medication and Treatment Categories
Conventional autoimmune disease medication falls into five broad categories, each targeting a different point in the inflammatory cascade. The table below compares them side by side so you can see how their mechanisms, typical uses, and trade-offs differ before discussing options with your rheumatologist or immunologist.
Treatment Category | Mechanism | Typical Use | Key Trade-Offs |
|---|---|---|---|
NSAIDs (e.g., ibuprofen, naproxen) | Block COX-1/COX-2 enzymes, reducing inflammatory prostaglandin synthesis | First-line therapy for most patients with axial spondyloarthritis per 2026 ACR guidelines | Chronic NSAID use causes gastric mucosal injury, renal impairment, increased cardiovascular risk, and impaired gastrointestinal mucosal barrier function and healing |
Corticosteroids (e.g., prednisone) | Corticosteroids (glucocorticoids) are used as short-term bridging therapy alongside conventional synthetic DMARDs to manage flares and rapidly improve symptoms while the DMARD takes effect, though guidelines vary and this is generally recommended only on a case-by-case basis (e.g., for patients with high disease activity) rather than for everyone | Corticosteroids should be tapered rather than abruptly discontinued, with tapering generally needed when therapy has lasted more than about three weeks; long-term use is linked to osteoporosis, metabolic disturbance, and increased infection risk | |
Conventional synthetic DMARDs (e.g., methotrexate, azathioprine) | Moderate-to-severe inflammatory arthritis; peripheral arthritis in spondyloarthritis | Conventional synthetic DMARDs generally require regular blood monitoring for hematologic, renal, and hepatic toxicity, typically including full blood count, renal function (serum creatinine/eGFR), and liver function tests, although monitoring requirements vary by agent—for example, no routine blood tests are required for hydroxychloroquine unless it is combined with other treatment | |
Biologics and targeted synthetic DMARDs (e.g., adalimumab, tocilizumab, JAK inhibitors) | In the ATLAS trial, 58.2% of adalimumab-treated patients with active ankylosing spondylitis achieved an ASAS20 response at Week 12, compared with 20.6% of placebo-treated patients; infection risk, malignancy surveillance, and high cost are ongoing concerns | ||
Replacement Therapy (e.g., thyroid hormone, insulin) | Replaces hormones destroyed by autoimmune attack on target glands | Hashimoto's thyroiditis, Type 1 diabetes |
The 2026 ACR axial spondyloarthritis guidelines recommend switching to a therapy with a different mechanism of action if initial biologic or targeted treatment fails, and advise reassessing potential causes of non-response after failure of two or more therapeutic classes. Treatment choice is also shaped by extra-musculoskeletal manifestations. In patients with axial spondyloarthritis, the presence of acute anterior uveitis or inflammatory bowel disease favors use of monoclonal antibodies against TNF (with JAK inhibitors also an option for IBD), while psoriasis favors the use of IL-17 inhibitors.
Conventional standard therapies for autoimmune diseases share the logic of broadly suppressing immune response intensity rather than correcting its direction, whereas newer targeted immunotherapies aim to more selectively modulate the immune system, and long-term broad-spectrum immunosuppression brings cumulative toxicities including infection, osteoporosis, metabolic disturbance, and cardiovascular events. Many patients therefore look for complementary approaches that support immune balance without replacing necessary medication.
Book a Consultation With Dr. Akash Chandawarkar
What Is the Root Cause Of Autoimmune Disease?
Autoimmune diseases share a common etiologic framework involving the convergence of genetic predisposition, environmental exposures (such as infections, diet, microbiome alterations, and hormonal influences), and immune dysregulation, rather than a single causative factor. These drivers form the foundation of any root-cause-informed treatment strategy.
A 2026 Frontiers in Immunology review supports the concept of "microbiome-orchestrated cross-organ immunity," in which gut-derived microbial metabolites and immune cells influence disease activity in joints, kidneys, skin, lungs, and the central nervous system. Short-chain fatty acids, bile acid derivatives, and tryptophan catabolites function as biochemical checkpoints linking intestinal barrier integrity to tissue-specific inflammation.
Marked expansion of Ruminococcus gnavus occurs in systemic lupus erythematosus patients with high disease activity and lupus nephritis, while Prevotella copri is expanded in new-onset, untreated rheumatoid arthritis patients compared with healthy controls. These shifts are not merely correlations. When researchers colonized animal models with these bacteria, inflammatory disease worsened, suggesting the microbes may actively drive disease activity.
Hormonal factors also contribute. Epidemiological estimates indicate that approximately 78% to 80% of people affected by autoimmune diseases are women, though some newer research suggests the figure may be closer to 67%. The female-to-male ratio is typically around 3:1 in rheumatoid arthritis, with estimates ranging from about 2:1 to 3:1 depending on the population and age group studied. The ratio is approximately 7–9:1 for systemic lupus erythematosus, and about 16:1 for Sjögren's syndrome. This disparity is shaped in part by the bidirectional relationship between sex hormones and gut microbial communities.
Conventional autoimmune disease treatment often focuses on symptom control rather than addressing these root drivers. An integrative, root-cause-informed approach that incorporates lab analysis of inflammatory markers, hormonal panels, and gut health indicators offers a more precise starting point for personalized care. Understanding what drives the disease long-term is only half the picture; patients also need to know what sets off sudden flares.
What Triggers an Autoimmune Disease Flare-Up?
Common triggers for autoimmune disease flares include infections, psychological stress, poor sleep, medication changes or lapses, overexertion, sun or UV exposure, smoking, hormonal shifts, and environmental exposures such as air pollution; alcohol's effect is dose-dependent, with high intake harmful but low-to-moderate intake potentially protective in some conditions like lupus and rheumatoid arthritis. Infection, stress, and sleep disruption recur as triggers across many autoimmune diseases, while treatment interruption is not consistently identified as a trigger in the reviewed evidence.
The most common autoimmune disease flare-up triggers, organized by category:
Infectious Triggers: In genetically susceptible individuals, viral or bacterial infections can provoke autoimmune reactivation and flares through mechanisms including molecular mimicry, epitope spreading, bystander activation, and compromised mucosal barrier disruption with microbial translocation
Sleep Deprivation: Disrupts immune regulation and amplifies inflammatory signaling
Overexertion: Strenuous or prolonged physical stress, especially when unaccustomed or sustained beyond an individual's tolerance, can cause transient immune dysfunction—including Th1/Th2 imbalance—that temporarily destabilizes immune balance
Environmental Toxins: Inhaled particulates from environmental pollutants accumulate in macrophages in lung-associated lymph nodes over years, compromising immune surveillance via direct effects on immune cell function and lymphoid architecture, while air pollution more broadly can also affect the wider immune system, including the gastrointestinal tract
Hormonal Shifts: Menstrual cycle changes, pregnancy, and menopause alter immune activity
In systemic lupus erythematosus, repeated flares—regardless of severity—significantly increase the risk of subsequent irreversible organ damage accrual, with each additional flare raising the risk by about 14% (unadjusted HR 1.14, 95% CI 1.09–1.19); similar associations between flare frequency and damage accrual have been observed in other autoimmune diseases such as rheumatoid arthritis, so early clinical intervention matters beyond symptom relief. Identifying personal triggers through symptom tracking and lab work, including inflammatory markers, hormone panels, and gut health indicators, is a practical first step toward reducing flare frequency.
Diet and Lifestyle: How To Reduce Autoimmune Disease Symptoms
Diet and lifestyle modifications offer accessible ways to reduce autoimmune disease activity. Evidence strength varies across interventions, and none replaces medical treatment, yet several strategies have meaningful clinical support.
Mediterranean Diet (Strong Evidence): In a 12-week randomized feeding trial of overweight and obese rheumatoid arthritis patients, the Mediterranean diet produced a significantly greater reduction in DAS28 disease activity scores than a low-fat high-carbohydrate diet (p=0.02), despite no statistically significant difference in weight loss between groups. The Mediterranean diet's emphasis on olive oil, fish, legumes, vegetables, and whole grains is associated in many observational studies with increased short-chain fatty acid production and fiber-degrading bacteria, though a systematic review of randomized controlled trials and observational studies found no clear, consistent evidence of a MedDiet effect on gut microbiota composition or metabolism.
High-Fiber, Anti-Inflammatory Eating (Moderate Evidence): A 28-day high-fiber dietary intervention in rheumatoid arthritis patients increased circulating regulatory T cells, improved Th1/Th17 balance, reduced markers of bone erosion, and improved patient-reported outcomes. Butyrate, produced by microbial fermentation of dietary fiber, promotes regulatory T-cell differentiation and expansion while limiting Th17 polarization by suppressing IL-17, Rorα, and Rorγt expression, though its Treg-promoting effect is concentration-dependent and requires TGF-β1, with higher butyrate concentrations instead inducing T-bet and IFN-γ.
Omega-3 Fatty Acids (Moderate Evidence): Meta-analyses generally support a beneficial effect of marine omega-3 fatty acids on pain-related outcomes, morning stiffness, and NSAID use in rheumatoid arthritis, especially when supplementation lasted at least 3 months and provided at least 2.7 g/day of EPA and DHA, though the most rigorous meta-analysis found that only the reduction in NSAID consumption reached statistical significance, while improvements in tender joint count, swollen joint count, morning stiffness, and physical function were non-significant trends.
Gluten-Free and Dairy-Free Trials (Preliminary Evidence): Some patients with specific autoimmune conditions report symptom improvement on elimination diets. Overly restrictive eating can create stress, nutrient gaps, and social strain, and in rheumatoid arthritis, professional bodies such as the American College of Rheumatology recommend adherence to a Mediterranean-style anti-inflammatory diet and advise against formally defined diets such as vegan, intermittent fasting, elimination, gluten-free, and paleo diets.
Foods To Emphasize: Build meals around omega-3-rich fish, fiber-rich vegetables and legumes, colorful antioxidant-dense produce, olive oil, and fermented foods. Each of these supports the microbial diversity and short-chain fatty acid production described above, which in turn helps regulate immune activity.
Foods To Limit: Focus on reducing processed foods, refined sugar, excess alcohol, and high-sodium foods. High sodium chloride concentrations induce SGK1, which promotes IL-23R expression and enhances Th17 cell differentiation in vitro and in vivo; however, the resulting Th17 phenotype is context-dependent, becoming pro-inflammatory and pathogenic only when T cell stimulation occurs in a proinflammatory, TGF-β-low cytokine microenvironment, while high-NaCl conditions can otherwise induce an anti-inflammatory Th17 fate.
Exercise, Sleep, and Stress Management (Strong Evidence For Symptom Reduction): Moderate-intensity physical activity shifts gut microbiota toward more butyrate-producing taxa, though intense or long-duration exercise can reduce SCFA-producing bacteria and short-term interventions in overweight or obese adults may not change fecal SCFAs. Disruption of circadian alignment leads to loss of microbial rhythmicity and gut dysbiosis, which is connected to host metabolic dysfunction such as obesity, insulin resistance, and type 2 diabetes; animal models demonstrate causality, but human evidence remains largely correlational and limited by methodological constraints. Consistent sleep timing, paced physical activity, and evidence-based stress reduction practices each contribute to lower baseline inflammatory tone. Beyond lifestyle, a newer wave of therapies is being studied for patients whose disease does not respond fully to conventional treatment.
Emerging and Complementary Therapies For Autoimmune Disease Treatment
CAR-T Cell Therapy (Investigational): Anti-CD19 CAR T-cell therapy has produced deep, drug-free long-term remission in refractory autoimmune diseases including systemic lupus erythematosus, inflammatory myopathies, and systemic sclerosis. The number of autoimmune patients treated with CAR-T worldwide remains limited; as of a September 2026 PubMed-indexed systematic review, published peer-reviewed cases totaled 115 patients across 38 studies, and existing evidence is predominantly from small-sample, single-arm, open-label studies lacking randomized controlled data. CAR-T is currently limited to refractory disease in specialized centers.
Medically Supervised Peptide Therapy: Peptides are short chains of amino acids that act as signaling molecules and can target inflammation and immune modulation with greater specificity than broad immunosuppressants. Several peptides are relevant to autoimmune and inflammatory conditions:
BPC-157 (Body Protective Compound 157): According to a 2025 narrative review in Current Reviews in Musculoskeletal Medicine, BPC-157's proposed anti-inflammatory actions include positive modulation of endothelial nitric oxide synthase (eNOS) via the Akt-eNOS axis, and other sources propose upregulation of the antioxidant enzyme heme oxygenase-1 (HO-1) and suppression of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. It targets systemic inflammation, tissue repair, and gut mucosal integrity.
TB500 (Thymosin Beta-4): In preclinical (in vitro and animal) studies, largely using full-length thymosin beta-4 rather than the TB-500 heptapeptide, TB-500/Tβ4 reduces inflammatory signaling through suppression of NF-κB pathway activation and modulates the balance between M1 and M2 macrophage polarization; no human clinical trial has yet demonstrated that TB-500 reduces clinically meaningful inflammation. It is used for soft tissue inflammation and wound repair.
KPV: KPV is the C-terminal tripeptide (Lys-Pro-Val, residues 11–13) of alpha-melanocyte-stimulating hormone that is taken up into cells via the PepT1 transporter and blocks nuclear translocation of the NF-kB p65RelA subunit by competing with importin-alpha3 binding, while also stabilizing IkB-alpha. In preclinical mouse studies, orally administered KPV (Lys-Pro-Val) has demonstrated anti-inflammatory effects in DSS- and TNBS-induced colitis models, reducing body weight loss, colonic myeloperoxidase activity, histological signs of inflammation, and pro-inflammatory cytokine mRNA levels; however, this evidence is limited to animal and cell-culture experiments, with no human clinical trials conducted. It targets gut inflammation and may reduce risks associated with inflammatory bowel disease.
GHK-Cu (Copper Peptide): GHK-Cu reduces inflammation and free radical damage, stimulates collagen and elastin synthesis, and promotes new blood vessel growth, though its anti-inflammatory effect is modulatory and pro-resolution rather than simply suppressive, and its collagen and elastin increases are modest and dose-dependent.
Honest evidence framing is essential. Peptides for autoimmune disease are not FDA-regulated, and most clinical evidence remains preclinical. BPC-157 remains an investigational peptide with no approved formulation, no validated dosing regimen, and no Phase II clinical trial with published results despite over three decades of preclinical research, although a Phase II ulcerative colitis trial (PL-14736) was reportedly completed by Pliva without its data ever being published in a peer-reviewed journal. Medical supervision is what separates a potentially beneficial protocol from an uncontrolled risk.
Why Mirror Plastic Surgery Leads in Medically Supervised Peptide Therapy
Mirror Plastic Surgery offers personalized, physician-led peptide protocols for a range of health concerns in the St. Petersburg and Tampa Bay area of Florida, with remote service delivery available across the United States, including Hawaii and Alaska.
Peptide therapies at Mirror Plastic Surgery are led by Dr. Akash Chandawarkar, MD, a Harvard-educated physician, Johns Hopkins-trained plastic surgeon, Stanford Biodesign Innovation Fellowship alumnus, and board-certified member of the American Board of Plastic Surgery. Dr. Akash studied neuroscience and nuclear engineering at MIT before completing his medical degree through the Harvard-MIT Division of Health Sciences and Technology, which gives him a deep foundation in physiology, metabolic health, and the body's capacity for recovery.
The Mirror Plastic Surgery model differs from online peptide retailers and generalized telemedicine platforms in four concrete ways:
Lab-Driven Personalization: Consultations of 30–60 minutes include in-depth review of thyroid, liver, kidney, diabetes markers, and hormone panels. If labs are not available, they are ordered before any protocol begins, so every subsequent decision, from peptide selection to dosing, starts from your actual physiology rather than a template.
Custom Peptide Stacks: Based on each patient's labs and physiology, Dr. Akash designs individualized peptide combinations, such as the Glow Stack (GHK-Cu, BPC-157, TB500) for systemic inflammation and tissue repair. This tailored approach replaces one-size-fits-all protocols.
Quality Sourcing: Peptides are sourced from reputable providers with rigorous batch testing, ensuring product quality, purity, and accurate dosage, which is a critical distinction given the unregulated nature of the peptide market.
24/7 Concierge Access: Patients have direct access to Dr. Akash via text for ongoing support, dosing questions, and refill requests throughout their protocol, creating continuity and rapid troubleshooting.
Some clients have reported reversal of autoimmune conditions such as psoriasis* through medically supervised peptide protocols at Mirror Plastic Surgery. Results vary by individual, and no outcome is guaranteed. Peptide therapy works best as part of a broader team, which is why coordinating with your existing providers matters.
Start Your Personalized Peptide Plan
How To Build Your Care Team
Effective autoimmune disease treatment almost always requires more than one provider. A rheumatologist is the appropriate specialist for diagnosis, conventional medication management, and monitoring of disease progression and organ involvement in musculoskeletal and systemic autoimmune rheumatic diseases. Patients with complex or refractory presentations can also seek a second opinion from another rheumatologist or an academic medical center.
A functional medicine or integrative provider can complement conventional care by addressing root-cause drivers such as gut microbiome health, hormonal balance, nutritional status, and stress physiology that often fall outside the scope of most rheumatology visits.
Medically supervised peptide therapy, as offered at Mirror Plastic Surgery, is designed to complement conventional care rather than replace it. Dr. Akash works alongside each patient's existing care team, using lab data to identify inflammatory drivers and design peptide protocols that support, and do not interfere with, ongoing medical management. Patients should disclose all peptide protocols to their rheumatologist to ensure coordinated, safe care.
Frequently Asked Questions
Can You Reverse Autoimmune Disease?
Full reversal (functional cure) of autoimmune disease is not currently achievable in most patients; it appears possible only in rare, selected cases through trigger eradication, immune reset, or profound immune depletion. A small subset of patients with autoimmune diseases, such as ACPA-negative rheumatoid arthritis and mild IgA nephropathy, can achieve long-term drug-free remission, though this "functional cure" is rare and does not imply complete eradication of genetic or immunologic susceptibility to relapse. For moderate-to-severe systemic lupus erythematosus (SLE), the 2025 ACR guidelines recommend immunosuppressants and biologics, and real-world registry data show that most such patients receive ongoing systemic treatment to maintain control.
The most compelling remission data comes from CAR-T cell therapy in refractory cases. In a case series of 15 patients with severe systemic lupus erythematosus, idiopathic inflammatory myositis, or systemic sclerosis, a single CD19-directed CAR-T infusion after fludarabine or cyclophosphamide conditioning led to remission in all patients (DORIS remission in SLE, ACR-EULAR major clinical response in myositis, and reduced EUSTAR activity scores in systemic sclerosis), with immunosuppressive therapy completely stopped and autoantibody seroconversion and normalization of inflammatory markers observed over up to 2 years of follow-up. Relapse can still occur after CAR-T, and CAR-T remains investigational and limited to specialized centers, but in autoimmune disease it appears to have a generally manageable safety profile: severe adverse events are rare, CRS and ICANS occur in 70.4% and 4.3% of patients respectively (mostly low-grade), and while transient hematologic toxicity, hypogammaglobulinemia, and infections are frequently reported, prolonged cytopenia and severe infection are infrequent. It is not a general cure.
For most patients, the realistic goal is durable remission with optimized conventional therapy, supported by root-cause-informed lifestyle changes and, where appropriate, medically supervised complementary protocols.
What Not To Do With Autoimmune Disease?
Several behaviors consistently worsen autoimmune disease outcomes or increase flare risk:
Abrupt Medication Changes: In patients with established rheumatoid arthritis in remission or stable low disease activity, stopping or withdrawing biologics, DMARDs, or corticosteroids increases the risk of flare and rebound inflammation, with randomized trial data showing substantially more flares after stopping TNF inhibitors (51.2%) than continuing them (18.2%) over 12 months; such withdrawal should be done cautiously and with monitoring. As discussed in the medication section, stopping TNF inhibitors roughly triples flare risk compared with continuing them.
Unregulated Supplements and Online Peptides: Purchasing peptides from unverified online sources carries significant risks, including unknown purity, incorrect dosing, and lack of medical supervision.
Immune-Stimulating Products: Products marketed to "boost" the immune system can worsen autoimmune activity by amplifying an already dysregulated immune response. This group includes certain herbal preparations and high-dose immune-stimulating supplements.
Extreme Elimination Diets Without Guidance: Aggressive dietary restriction without professional supervision can create nutrient deficiencies, worsen fatigue, and add psychological stress, which can destabilize disease activity.
Are Peptides Safe For Autoimmune Conditions?
In preclinical research, peptides like BPC-157 and KPV are considered mechanistically appropriate for autoimmune-driven inflammation because they suppress inflammatory signaling—KPV primarily through MC3R or MC5R-mediated NF-kB inhibition and cytokine modulation, and BPC-157 through gut-barrier restoration and NO-mediated anti-inflammatory effects—without broadly suppressing immune function, though neither is an approved or clinically proven treatment for autoimmune disease. This profile distinguishes them from immune-stimulating peptides. Exogenous LL-37, an immunostimulatory cathelicidin peptide implicated in autoimmune pathophysiology such as driving plasmacytoid dendritic cell activation and type I interferon in lupus and psoriasis, should be avoided in active autoimmune states.
Several important limitations still apply. Peptides are not FDA-regulated for autoimmune indications. For most popular and research-grade peptides, the evidence base is predominantly preclinical (animal and lab studies) with limited human clinical trial data, and only about 21% of indexed peptide literature is clinical-trial or meta-analysis grade, though several peptide-based drugs are FDA-approved and many more are progressing through clinical testing. Individual responses vary based on genetics, disease phenotype, existing medications, and overall health status. Medical supervision is essential. A physician must review labs, screen for contraindications (including active malignancy, which is treated as the standard theoretical contraindication for angiogenesis-promoting peptides such as BPC-157, reflecting an absence of human safety data rather than a proven tumor-promotion risk), and monitor for adverse effects throughout the protocol. Purchasing peptides without medical oversight removes all of these safeguards.
How Long Until Peptide Therapy Works For Autoimmune Conditions?
The timeline varies by peptide and condition. Some patients report initial improvements within the first hours to a week of beginning a peptide protocol, depending on the treated condition. Others notice gradual changes over several weeks as inflammation, sleep, energy, and pain levels shift in response to consistent dosing and lifestyle support.
Conclusion: Your Next Step in Autoimmune Disease Treatment
Autoimmune disease treatment is highly individualized. Conventional medication controls symptoms and prevents organ damage, yet it rarely addresses the root-cause drivers such as gut dysbiosis, hormonal imbalance, chronic stress, and nutritional deficiencies that sustain immune dysregulation. A root-cause-informed, physician-supervised approach that integrates lab analysis, lifestyle modification, and personalized peptide protocols offers a more precise path toward sustained remission and improved quality of life.
Mirror Plastic Surgery delivers that approach. Under the direct leadership of Dr. Akash Chandawarkar, who is Harvard-educated, Johns Hopkins-trained, and Stanford Biodesign Innovation Fellowship-trained, every autoimmune disease treatment protocol is built on each patient's own labs, physiology, and goals. Batch-tested peptide sourcing, 30–60 minute consultations, and 24/7 direct physician access set Mirror Plastic Surgery apart from both online peptide retailers and less personalized telemedicine platforms.
Schedule Your Lab-Driven Consultation
Disclaimer: Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results. Peptide therapies are not FDA-regulated; consult with a qualified physician before starting any treatment.
